The 5-HT 2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: Relationship to feeding behavior and impulse control

Neuropsychopharmacology

Volumn 37, Issue 5, 2012, Pages 1177-1191

  Higgins, Guy A ^a,b   Silenieks, Leo B ^a   Roßmann, Anne ^a   Rizos, Zoe ^c   Noble, Kevin ^c   Soko, Ashlie D ^c   Fletcher, Paul J ^b,c  

^a InterVivo Solutions Inc   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

5 HT 2C receptor; addiction; impulsivity; nicotine dependence; obesity; reward

Indexed keywords

LORCASERIN; NICOTINE; SODIUM CHLORIDE; 6 CHLORO 5 METHYL 1 ((2 (2 METHYLPYRID 3 YLOXY)PYRID 5 YL)CARBAMOYL)INDOLINE; 6-CHLORO-5-METHYL-1-((2-(2-METHYLPYRID-3-YLOXY)PYRID-5-YL)CARBAMOYL)INDOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 1 METHYL 1H 3 BENZAZEPINE; 8-CHLORO-2,3,4,5-TETRAHYDRO-1-METHYL-1H-3-BENZAZEPINE; AMINOPYRIDINE DERIVATIVE; BENZAZEPINE DERIVATIVE; INDOLE DERIVATIVE; NICOTINIC AGENT; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONED REFLEX; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; FEEDING BEHAVIOR; FOOD DEPRIVATION; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REINFORCEMENT; TOBACCO DEPENDENCE; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; DECISION MAKING; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG SELF ADMINISTRATION; EATING; IMPULSIVENESS; MOTOR ACTIVITY; PERCEPTIVE DISCRIMINATION; REACTION TIME; ROTAROD TEST; SPRAGUE DAWLEY RAT;

AMINOPYRIDINES; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; CHOICE BEHAVIOR; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; EATING; FEEDING BEHAVIOR; IMPULSIVE BEHAVIOR; INDOLES; MALE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; REINFORCEMENT (PSYCHOLOGY); ROTAROD PERFORMANCE TEST; SELF ADMINISTRATION; SEROTONIN RECEPTOR AGONISTS;

EID: 84858332463     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.303     Document Type: Article

References (79)

1. Bickel WK, Odum AL, Madden GJ (1999). Impulsivity and cigarette smoking: Delay discounting in current, never, and ex-smokers. Psychopharmacology 146: 447-454.
2. Bubar MJ, Cunningham KA (2007). Distribution of serotonin 5- HT2C receptors in the ventral tegmental area. Neuroscience 146: 286-297.
3. Burbassi S, Cervo L (2008). Stimulation of serotonin2C receptors influences cocaine-seeking behaviour in response to drugassociated stimuli in rats. Psychopharmacology 196: 15-27.
4. Clarke PBS, Fu DS, Jakubovic A, Fibiger HC (1988). Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 246: 701-708.
5. Clifton PG, Lee MD, Dourish CT (2000). Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and dfenfluramine on feeding patterns in the rat. Psychopharmacology 152: 256-267.
6. Cone RD (2005). Anatomy and regulation of the central melanocortin system. Nature Neuroscience 8: 571-578.
7. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al (1997). Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588.
8. Corrigall WA, Coen KM (1994). Dopamine mechanisms play at best a small role in the nicotine discriminative stimulus. Pharmacol Biochem Behav 48: 817-820.
9. Corrigall WA, Coen KM, Adamson L (1994). Self administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653: 278-284.
10. Corrigall WA, Franklin KB, Coen KM, Clarke PBS (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107: 285-289.
11. Cunningham KA, Fox RG, Anastasio NC, Bubar MJ, Stutz SJ, Moeller FG et al (2011). Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine vs sucrose-associated cues. Neuropharmacology 61: 513-523.
12. Desai RI, Barber DJ, Terry P (2003). Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology 167: 335-343.
13. Di Matteo V, Pierucci M, Esposito E (2004). Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 89: 418-429.
14. Diergaarde L, Pattil T, Poortvleit I, Hogenboom F, de Vries W, Schoffelmeer ANM et al (2008). Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats. Biol Psychiatry 63: 301-308.
15. Elangbam CS, Lightfoot RM, Yoon LW, Creech DR, Geske RS, Crumbley CW et al (2005). 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 53: 671-677.
16. Epstein DH, Preston KL, Stewart J, Shaham Y (2006). Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmacology 189: 1-16.
17. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al, the BLOSSOM trial group (2011). A oneyear randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab 96: 3067-3077.
18. Fields S, Collins C, Leraas K, Reynolds B (2009). Dimensions of impulsive behaviour in adolescent smokers and non-smokers. Exp Clin Psychol 17: 302-311.
19. Filip M, Cunningham KA (2003). Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. J Pharmacol Exp Ther 306: 734-743.
20. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA et al (2000). Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57: 75-81.
21. Fletcher PJ, Currie PJ, Chambers JW, Coscina DV (1993). Radiofrequency lesions of the PVN fail to modify the effects of serotonergic drugs on food intake. Brain Res 630: 1-9.
22. Fletcher PJ, Le AD, Higgins GA (2009a). Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res 172: 361-383.
23. Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA (2008). The 5-HT(2C) receptor agonist Ro60-0175 reduces cocaine selfadministration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology 33: 1402-1412.
24. Fletcher PJ, Tampakeras M, Sinyard J, Higgins GA (2007). Opposing effects of 5-HT2A and 5-HT2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology 195: 223-234.
25. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA (2009b). Characterising the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice. Neuropharmacology 57: 259-267.
26. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al, Varenicline Phase 3 Study Group (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296: 47-55.
27. Grottick AJ, Corrigall WA, Higgins GA (2001). Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology 157: 292-298.
28. Grottick AJ, Fletcher PJ, Higgins GA (2000). Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. J Pharmacol Exp Ther 295: 1183-1191.
29. Grottick AJ, Higgins GA (2000). Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 117: 197-208.
30. Guy-Grand B, Crepaldi G, Lefebvre P, Apfelbaum M, Gries A, Turner P (1989). International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142-1145.
31. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA et al (2009). 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 34: 1958-1967.
32. Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Drugs 67: 27-55.
33. Hayes DJ, Mosher TM, Greenshaw AJ (2009). Differential effects of 5-HT2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats. Behav Brain Res 197: 323-330.
34. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL et al (2002). Activation of central melanocortin pathways by fenfluramine. Science 297: 609-611.
35. Henningfield JE, Shiffman S, Ferguson SG, Gritz ER (2009). Tobacco dependence and withdrawal: Science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 123: 1-16.
36. Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002). Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71: 691-700.
37. Higgins GA, Fletcher PJ (2003). Serotonin and reward: Focus on 5-HT2C receptors. Eur J Pharmacol 480: 151-162.
38. Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554.
39. Hughes JR, Neely J, Naud S (2004). Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99: 29-38.
40. Keath JR, Lacoviello MP, Barrett LE, Mansvelder HD, McGehee DS (2007). Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurones. J Neurophysiol 98: 3388-3396.
41. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V et al (1997). SB242,084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609-620.
42. Kenny PJ (2011). Reward mechanisms in obesity: New insights and future directions. Neuron 69: 664-679.
43. Kolokotroni KZ, Rodgers RJ, Harrison AA (2011). Acute nicotine increases both impulsive choice and behavioural disinhibition in rats. Psychopharmacology 217: 455-473.
44. Mansvelder HD, Keath JR, McGehee DS (2002). Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905-919.
45. Miyata H, Ando K, Yanagita T (2002). Brain regions mediating the discriminative stimulus effects of nicotine in rats. Ann NY Acad Sci 965: 354-363.
46. Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M (2008). The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time task. Behav Brain Res 188: 412-415.
47. Niesewander JL, Acosta JI (2007). Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaineseeking behavior in rats. Behav Pharmacol 18: 791-800.
48. Nilsson BM (2006). 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential anti-obesity agents. J Med Chem 49: 4023-4034.
49. O'Connor EC, Parker D, Rollema H, Mead AN (2010). The a4b2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology 208: 365-376.
50. Pattij T, Vanderschuren LJMJ (2008). The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci 29: 192-199.
51. Pentkowski NS, Duke FD, Weber SM, Pockros LA, Teer AP, Hamilton EC et al (2011). Stimulation of medial prefrontal cortex serotonin 2C (5-HT2C) receptors attenuates cocaineseeking behavior. Neuropsychopharmacology 35: 2037-2048.
52. Pierucci M, Di Matteo V, Esposito E (2004). Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration. J Pharmacol Exp Ther 309: 109-118.
53. Popke EJ, Mayorga AJ, Fogle CM, Paule MG (2000). Effects of acute nicotine on several operant behaviours in rats. Pharmacol Biochem Behav 65: 247-254.
54. Quarta D, Naylor CG, Stolerman IP (2007). The serotonin2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology 193: 391-402.
55. Reavill C, Stolerman IP (1990). Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 99: 273-278.
56. Recker MD, Higgins GA (2002). The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro- 1H-phenalen-1-yl-1-phenyl-1,3,8- triaza-spiro[4.5] decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue. J Pharmacol Exp Ther 311: 652-658.
57. Robbins TW (2002). The 5-choice serial reaction time task: Behavioural pharmacology and functional neurochemistry. Psychopharmacology 163: 362-380.
58. Rodgers RJ, Holch P, Tallet AJ (2010). Behavioural satiety sequence (BSS): Separating wheat from chaff in the behavioural pharmacology of appetite. Pharmacol Biochem Behav 97: 3-14.
59. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2nACh receptors for smoking cessation. Trends Pharmacol Sci 28: 316-325.
60. Rose JE, Levin ED (1991). Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br J Addict 86: 605-609.
61. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 168: 3-20.
62. Shram MJ, Schoedel KA, Barlett C, Shazer RL, Anderson CM, Sellers EM (2011). Evaluation of the abuse potential evaluation of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther 89: 683-692.
63. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P et al (2007). CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52: 279-290.
64. Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG (2007). 5-HT2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur J Neurosci 25: 3115-3124.
65. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA et al (2008). Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5- tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 51: 305-313.
66. Smith JW, Stolerman IP (2009). Recognising nicotine: The neurobiological basis of nicotine discrimination. Handb Exp Pharmacol 192: 295-333.
67. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, APD356-004 Study Group. (2009). Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 17: 494-503.
68. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010). Multicentre, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 263: 245-256.
69. Stolerman IP, Mirza NR, Hahn B, Shoaib M (2000). Nicotine in an animal model of attention. Eur J Pharmacol 393: 147-154.
70. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espita S, Yuskin D et al (2008). Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325: 577-587.
71. Tonstad S, Tnnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, Varenicline Phase 3 Study Group. (2006). Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 296: 64-71.
72. Vickers SP, Clifton PG, Dourish CT, Tecott LH (1999). Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143: 309-314.
73. Vickers SP, Dourish CT, Kennett GA (2001). Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41: 200-209.
74. Volkow ND, O'Brien CP (2007). Issues for DSM-V: Should obesity be included as a brain disorder? Am J Psychiatry 164: 708-710.
75. Volkow ND, Wise RA (2005). How can drug addiction help us understand obesity? Nat Neurosci 8: 555-560.
76. Wacker DA, Miller KJ (2008). Agonists of the serotonin 5-HT2C receptor: Preclinical and clinical progression in multiple diseases. Curr Opin Drug Discov Dev 11: 438-445.
77. Winstanley CA, Olausson P, Taylor JR, Jentsch JD (2010). Insight into the relationship between impulsivity and substance abuse from studies using animal models. Alcoholism Clin Exp Res 34: 1306-1318.
78. Zaniewska M, McCreary AC, Przegalinski E, Filip M (2007). Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 571: 156-165.
79. Zhao-Shea R, Liu L, Soll LG, Improgo MR, Meyers EE, McIntosh JM et al (2011). Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology 36: 1021-1032.